MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 555273 | Name: KDU691
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KDU691 is a plasmodium PI4K inhibitor (IC50 values of 0.18 μM and 0.061 μM against hypnozoite forms and liver schizontsm, respectively). KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites.

Chemical Structure

KDU691
KDU691
CAS#1513879-19-0

Theoretical Analysis

MedKoo Cat#: 555273

Name: KDU691

CAS#: 1513879-19-0

Chemical Formula: C22H18ClN5O2

Exact Mass: 419.1149

Molecular Weight: 419.87

Elemental Analysis: C, 62.93; H, 4.32; Cl, 8.44; N, 16.68; O, 7.62

Price and Availability

Size Price Availability Quantity
50mg USD 650.00 2 Weeks
100mg USD 950.00 2 Weeks
250mg USD 1,650.00 2 Weeks
500mg USD 2,450.00 2 Weeks
1g USD 3,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
KDU691; KDU-691; KDU 691;
IUPAC/Chemical Name
N-(4-chlorophenyl)-N-methyl-3-(4-(methylcarbamoyl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide
InChi Key
TYMFFISSODJRDV-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H18ClN5O2/c1-24-21(29)15-5-3-14(4-6-15)19-11-26-20-12-25-18(13-28(19)20)22(30)27(2)17-9-7-16(23)8-10-17/h3-13H,1-2H3,(H,24,29)
SMILES Code
ClC1=CC=C(N(C(C2=CN3C(C=N2)=NC=C3C4=CC=C(C(NC)=O)C=C4)=O)C)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
KDU691, an imidazopyrazine with potent anti-parasitic activity against blood stage schizonts, gametocytes and liver stages, is a Plasmodium PI4K inhibitor.
In vitro activity:
Finally, in addition to GNF179, this study demonstrated that the Plasmodium PI4K-specific inhibitor KDU691 is highly inhibitory against P. malariae and P. falciparum. Reference: J Antimicrob Chemother. 2021 Jul 15;76(8):2079-2087. https://pubmed.ncbi.nlm.nih.gov/34021751/
In vivo activity:
Rhesus monkeys were infected with P. cynomolgi sporozoites, and compounds were dosed orally. Both the KDU691 and LMV599 compounds were fully protective when administered prophylactically, and the more potent compound LMV599 achieved protection as a single oral dose of 25 mg/kg of body weight. I Reference: Antimicrob Agents Chemother. 2016 Apr 22;60(5):2858-63. https://pubmed.ncbi.nlm.nih.gov/26926645/
Solvent mg/mL mM
Solubility
DMSO:PBS (pH 7.2) (1:9) 0.1 0.24
Ethanol 10.0 23.82
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 419.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Dembele L, Aniweh Y, Diallo N, Sogore F, Sangare CPO, Haidara AS, Traore A, Diakité SAS, Diakite M, Campo B, Awandare GA, Djimde AA. Plasmodium malariae and Plasmodium falciparum comparative susceptibility to antimalarial drugs in Mali. J Antimicrob Chemother. 2021 Jul 15;76(8):2079-2087. doi: 10.1093/jac/dkab133. PMID: 34021751. 2. Dembele L, Ang X, Chavchich M, Bonamy GMC, Selva JJ, Lim MY, Bodenreider C, Yeung BKS, Nosten F, Russell BM, Edstein MD, Straimer J, Fidock DA, Diagana TT, Bifani P. The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites. Sci Rep. 2017 May 24;7(1):2325. doi: 10.1038/s41598-017-02440-6. PMID: 28539634; PMCID: PMC5443816. 3. Zeeman AM, Lakshminarayana SB, van der Werff N, Klooster EJ, Voorberg-van der Wel A, Kondreddi RR, Bodenreider C, Simon O, Sauerwein R, Yeung BK, Diagana TT, Kocken CH. PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2858-63. doi: 10.1128/AAC.03080-15. PMID: 26926645; PMCID: PMC4862498.
In vitro protocol:
1. Dembele L, Aniweh Y, Diallo N, Sogore F, Sangare CPO, Haidara AS, Traore A, Diakité SAS, Diakite M, Campo B, Awandare GA, Djimde AA. Plasmodium malariae and Plasmodium falciparum comparative susceptibility to antimalarial drugs in Mali. J Antimicrob Chemother. 2021 Jul 15;76(8):2079-2087. doi: 10.1093/jac/dkab133. PMID: 34021751. 2. Dembele L, Ang X, Chavchich M, Bonamy GMC, Selva JJ, Lim MY, Bodenreider C, Yeung BKS, Nosten F, Russell BM, Edstein MD, Straimer J, Fidock DA, Diagana TT, Bifani P. The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites. Sci Rep. 2017 May 24;7(1):2325. doi: 10.1038/s41598-017-02440-6. PMID: 28539634; PMCID: PMC5443816.
In vivo protocol:
1. Zeeman AM, Lakshminarayana SB, van der Werff N, Klooster EJ, Voorberg-van der Wel A, Kondreddi RR, Bodenreider C, Simon O, Sauerwein R, Yeung BK, Diagana TT, Kocken CH. PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2858-63. doi: 10.1128/AAC.03080-15. PMID: 26926645; PMCID: PMC4862498.
1: Orjuela-Sanchez P, Villa ZH, Moreno M, Tong-Rios C, Meister S, LaMonte GM, Campo B, Vinetz JM, Winzeler EA. Developing Plasmodium vivax Resources for Liver Stage Study in the Peruvian Amazon Region. ACS Infect Dis. 2018 Apr 13;4(4):531-540. doi: 10.1021/acsinfecdis.7b00198. Epub 2018 Mar 15. PubMed PMID: 29542317. 2: Dembele L, Ang X, Chavchich M, Bonamy GMC, Selva JJ, Lim MY, Bodenreider C, Yeung BKS, Nosten F, Russell BM, Edstein MD, Straimer J, Fidock DA, Diagana TT, Bifani P. The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites. Sci Rep. 2017 May 24;7(1):2325. doi: 10.1038/s41598-017-02440-6. PubMed PMID: 28539634; PubMed Central PMCID: PMC5443816. 3: Zeeman AM, Lakshminarayana SB, van der Werff N, Klooster EJ, Voorberg-van der Wel A, Kondreddi RR, Bodenreider C, Simon O, Sauerwein R, Yeung BK, Diagana TT, Kocken CH. PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2858-63. doi: 10.1128/AAC.03080-15. Print 2016 May. PubMed PMID: 26926645; PubMed Central PMCID: PMC4862498.

View History

Purpuride

Purpuride